What is the role of SGLT2 inhibitors in heart failure, regardless of diabetes status?

• A. Reduce HF hospitalizations and CV death; beneficial in HFrEF and HFpEF
• B. Primarily lower glucose; no HF benefit
• C. Increase diuresis only; no mortality effect
• D. Replace diuretic therapy in HF

Answer: (A)

The main idea is that SGLT2 inhibitors provide heart-failure benefits that go beyond glucose lowering, and these benefits apply regardless of diabetes status. In heart failure with reduced ejection fraction, trials with dapagliflozin and empagliflozin showed fewer hospitalizations for heart failure and a lower risk of cardiovascular death. In heart failure with preserved ejection fraction, empagliflozin likewise reduced heart-failure hospitalizations and improved outcomes, extending benefit to patients without diabetes. The effect isn’t just about lowering blood sugar; these drugs aid in volume management and have broader cardio-renal benefits. They act through multiple mechanisms—natriuresis and diuresis contribute to volume relief, but they also improve renal protection, influence myocardial energy use, and reduce inflammation and fibrosis. Clinically, they are added to standard heart-failure therapies and are not meant to replace diuretics.